Overview
- This week Defense Secretary Pete Hegseth announced a new policy to screen active-duty and reserve service members age 30 and older for low testosterone and to offer voluntary replacement therapy when clinicians recommend it.
- Major endocrine and urology societies advise testing only for patients with consistent symptoms and confirmatory early-morning measurements, and they warn routine age-based screening can produce false positives and lead to unnecessary treatment.
- Clinicians caution that inappropriate testosterone therapy can sharply reduce sperm production and shrink testicles, create high red blood cell counts that raise clot risk, increase atrial arrhythmias and fractures, and require ongoing monitoring that may complicate deployments and family planning.
- The Pentagon has not released start dates, testing protocols, sex-based rules, cost estimates, or criteria for confirming abnormal results, and experts say rolling out population screening before publishing those details risks overdiagnosis and uneven care.
- Supporters say broader testing could find reversible causes of low testosterone such as obesity or poor sleep and could generate data on younger service members, but major trials that shaped recent FDA label changes studied older, symptomatic men and do not prove benefit for a younger, fit force.